PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
S Wee, Z Jagani, KX Xiang, A Loo, M Dorsch, YM Yao… - Cancer research, 2009 - AACR
The RAS pathway is one of the most frequently deregulated pathways in cancer. RAS
signals through multiple effector pathways, including the RAF/mitogen-activated protein …
signals through multiple effector pathways, including the RAF/mitogen-activated protein …
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
E Halilovic, QB She, Q Ye, R Pagliarini, WR Sellers… - Cancer research, 2010 - AACR
Mutational activation of KRAS is a common event in human tumors. Identification of the key
signaling pathways downstream of mutant KRAS is essential for our understanding of how to …
signaling pathways downstream of mutant KRAS is essential for our understanding of how to …
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
JA McCubrey, LS Steelman, SL Abrams, JT Lee… - Advances in enzyme …, 2006 - Elsevier
The Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signaling cascades play critical roles in the
transmission of signals from growth factor receptors to regulate gene expression and …
transmission of signals from growth factor receptors to regulate gene expression and …
Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy
K Yu, L Toral-Barza, C Shi, WG Zhang… - Cancer biology & …, 2008 - Taylor & Francis
While small molecule inhibitors of the phosphatidylinositide-3-kinase (PI3K) are expected to
impact the development of new cancer therapy, the tumor types and underlying cellular …
impact the development of new cancer therapy, the tumor types and underlying cellular …
[HTML][HTML] RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are
available to treat KRAS mutant cancers. We used two independent reverse genetic …
available to treat KRAS mutant cancers. We used two independent reverse genetic …
ERK inhibition overcomes acquired resistance to MEK inhibitors
G Hatzivassiliou, B Liu, C O'Brien, JM Spoerke… - Molecular cancer …, 2012 - AACR
Abstract The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most
commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several …
commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several …
Resistance to MEK inhibitors: should we co-target upstream?
PI Poulikakos, DB Solit - Science signaling, 2011 - science.org
Aberrant activation of the ERK pathway is common in human tumors. This pathway consists
of a three-tiered kinase module [comprising the kinases RAF, mitogen-activated protein …
of a three-tiered kinase module [comprising the kinases RAF, mitogen-activated protein …
[HTML][HTML] Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
H Ebi, RB Corcoran, A Singh, Z Chen… - The Journal of …, 2011 - Am Soc Clin Investig
Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human
cancers when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK …
cancers when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK …
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
A Hollestelle, F Elstrodt, JHA Nagel… - Molecular cancer …, 2007 - AACR
Constitutive activation of the phosphatidylinositol-3-OH kinase (PI3K) and RAS signaling
pathways are important events in tumor formation. This is illustrated by the frequent genetic …
pathways are important events in tumor formation. This is illustrated by the frequent genetic …
[HTML][HTML] MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance
K Zmajkovicova, V Jesenberger, F Catalanotti… - Molecular cell, 2013 - cell.com
Summary The Raf/MEK/ERK and PI3K/Akt pathways are prominent effectors of oncogenic
Ras. These pathways negatively regulate each other, but the mechanism involved is …
Ras. These pathways negatively regulate each other, but the mechanism involved is …
相关搜索
- kras mutant cancer cells
- mek inhibitor stat3 activation
- mek inhibitors acquired resistance
- pik3ca mutation mek erk
- pik3ca mutation tumor growth
- pathway mutations cell lines
- pathway mutations breast cancer
- pi3k inhibitors combined targeting
- pi3k inhibitors anticancer strategy
- mek inhibition cancer cells
- pik3ca mutation mutant kras
- tumor growth mek erk
- tumor growth mutant kras
- erk inhibition acquired resistance